Thomson Reuters today announced the appointment of Kristin Peck to the company’s board of directors with immediate effect.
Peck is Executive Vice President and President of U.S. Operations at Zoetis, a NYSE-listed global leader in the discovery, development, manufacture and commercialization of animal health medicines and vaccines that was spun off by Pfizer in 2013.
Peck was previously group president at Zoetis, responsible for global manufacturing and supply, global poultry, global diagnostics, corporate development and new product marketing and global market research. In this role she led the Zoetis Supply Network Strategy, the Zoetis Digital Strategy and the acquisition of Abbott Animal Health.
She is also a member of the Advisory Board for the Deming Center for Quality, Productivity and Competitiveness at Columbia Business School.
Rob Frasca Talks Ndau as an Adaptive Store of ValueGo to article >>
We surely welcome Kristin’s perspective to our boardroom.
Peck has also served as Executive Vice President, Worldwide Business Development and Innovation at Pfizer Inc. and as a member of Pfizer’s Executive Leadership Team where she was responsible for Pfizer’s merger and acquisition, licensing, venture capital, alliance management and innovative business model activities.
Prior to joining Pfizer, Peck focused on strategy and merger-related issues in the pharmaceutical and financial services industries at the Boston Consulting Group (BCG). She began her career in private equity and real estate finance at The Prudential Realty Group, The O’Connor Group and J.P. Morgan.
David Thomson, chairman of Thomson Reuters, said: “Kristin’s strategic and innovative business model experience has focused on global markets and deep customer interactions. “Her passion for talent and leadership development bodes well for our future. We surely welcome Kristin’s perspective to our boardroom.”